Angle PLC - Data Supporting FDA Approval Published in Journal Page 1

DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNAL Publication of Results from ANGLE’s Parsortix PC1 System Validates Use of Parsortix System for CTC Isolation and Harvesting in Metastatic Breast Cancer GUILDFORD, SURREY / ACCESSWIRE / August …

DATA SUPPORTING FDA APPROVAL PUBLISHED IN TOP-QUALITY JOURNAL

Publication of results from ANGLE’s Parsortix PC1 system validates use of Parsortix system for CTC isolation and harvesting in metastatic breast cancer

GUILDFORD, SURREY / ACCESSWIRE / August 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a leading liquid biopsy company providing innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of one of the Company’s clinical studies submitted to the FDA for De Novo approval of the Parsortix PC1 System.

We are a standout news service and fast becoming a disruptor in the industry. We deliver regional, national and global news to thousands of customers worldwide. We are also leaders in social engagement, targeting and analytics.